Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Minority Interest (2020 - 2025)

Barinthus Biotherapeutics' Minority Interest history spans 6 years, with the latest figure at $84000.0 for Q4 2025.

  • For Q4 2025, Minority Interest fell 20.75% year-over-year to $84000.0; the TTM value through Dec 2025 reached $84000.0, down 20.75%, while the annual FY2025 figure was $84000.0, 20.75% down from the prior year.
  • Minority Interest reached $84000.0 in Q4 2025 per BRNS's latest filing, down from $96000.0 in the prior quarter.
  • In the past five years, Minority Interest ranged from a high of $175.5 million in Q1 2021 to a low of $84000.0 in Q4 2025.
  • Average Minority Interest over 5 years is $9.0 million, with a median of $232000.0 recorded in 2023.
  • Peak YoY movement for Minority Interest: grew 11.76% in 2021, then tumbled 99.77% in 2022.
  • A 5-year view of Minority Interest shows it stood at $437000.0 in 2021, then plummeted by 30.21% to $305000.0 in 2022, then crashed by 30.82% to $211000.0 in 2023, then plummeted by 49.76% to $106000.0 in 2024, then decreased by 20.75% to $84000.0 in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Minority Interest are $84000.0 (Q4 2025), $96000.0 (Q3 2025), and $104000.0 (Q2 2025).